Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
MWN-AI** Summary
Polarean Imaging plc, a commercial-stage leader in advanced lung imaging, has announced a strategic collaboration with SimonMed Imaging, a prominent outpatient medical imaging provider in the United States. This partnership aims to enhance the accessibility of Polarean’s innovative Xenon MRI platform, which specializes in functional Magnetic Resonance Imaging (MRI) of the lungs. With over 170 facilities across 11 states, SimonMed is committed to integrating cutting-edge technology while emphasizing affordability and accessibility for patients.
The first installation of the Xenon MRI platform will take place at a SimonMed site in Scottsdale, Arizona, with plans to expand its use to additional locations as the collaboration develops. This integration aims to revolutionize the diagnostic capabilities available for pulmonary diseases, offering clinicians enhanced tools to visualize and assess lung function.
Dr. John Simon, CEO of SimonMed, emphasized the synergy between the organizations, as both share a mission to provide advanced diagnostic imaging technologies that are accessible to the community. He noted that Polarean's Xenon MRI technology offers unmatched insights for patients suffering from respiratory conditions such as asthma and COPD.
Christopher von Jako, CEO of Polarean, echoed this sentiment, highlighting the partnership’s potential to meet an urgent need for effective lung imaging solutions, thereby improving patient management and outcomes. Polarean Imaging stands at the forefront of hyperpolarization science with its FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is designed for evaluating lung ventilation in both adults and pediatric patients over the age of 12.
This collaboration marks a significant step towards the modernization of pulmonary imaging, with the potential to vastly improve the standards of care for millions of patients dealing with chronic respiratory diseases.
MWN-AI** Analysis
The recent collaboration between Polarean Imaging plc and SimonMed Imaging marks a significant development in the realm of lung imaging, leveraging advanced MRI technology to enhance patient diagnostics. As Polarean integrates its innovative Xenon MRI platform into SimonMed’s extensive network of over 170 facilities across 11 states, this partnership not only broadens access to cutting-edge imaging for pulmonary diseases but also positions both companies strategically within the growing medical imaging market.
For investors, this partnership could indicate a positive growth trajectory for Polarean. The FDA approval of XENOVIEW™ establishes Polarean as a leader in hyperpolarized gas imaging, while SimonMed’s commitment to affordability and accessibility aligns well with healthcare industry's demand for cost-effective solutions. The initial rollout in Scottsdale and potential for future installations presents further opportunities for revenue generation.
From a market trend perspective, the demand for non-invasive, radiation-free imaging methodologies is on the rise, particularly as chronic respiratory conditions impact over 500 million patients globally. The collaboration places Polarean at the forefront of a niche yet expanding market, addressing urgent unmet medical needs. Furthermore, the integration of AI technologies by SimonMed adds an additional layer of sophistication to the diagnostic process, enhancing overall value in patient care.
However, potential investors should remain vigilant concerning the regulatory landscape and market competition. While the collaboration offers promising growth prospects, monitoring quarterly performance reports, patient feedback on new technology, and expansion outcomes will be essential. In summary, Polarean’s partnership with SimonMed signals strong potential for innovation and market penetration, suggesting that now may be an opportune time for investors to consider increased exposure to Polarean’s stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DURHAM, NC and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage leader in advanced medical imaging focused on functional Magnetic Resonance Imaging ("MRI") of the lungs, announces a strategic collaboration with SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, to expand access to Polarean’s cutting-edge Xenon MRI platform.
SimonMed Imaging operates in over 170 facilities across 11 states, offering comprehensive medical imaging with cutting-edge technology and artificial intelligence, all with an emphasis on affordability and accessibility. This collaboration will integrate Polarean’s innovative Xenon MRI platform within SimonMed’s network, enhancing diagnostic capabilities and advancing the standard of care for patients with pulmonary diseases.
The first SimonMed site to adopt Polarean’s Xenon MRI platform will be in Scottsdale, Arizona, which is expected to be installed later this year, with scope to increase the number of sites installing systems as the collaboration matures.
The integration of Polarean’s Xenon MRI platform into SimonMed’s facilities represents a new business opportunity to expand the availability of functional lung imaging. This collaboration underscores both organizations’ dedication to advancing medical technologies that enhance patient care and improve clinical outcomes.
Dr. John Simon, Founder and CEO of SimonMed Imaging, stated : “At SimonMed, our mission is to bring the newest diagnostic imaging technologies to the community in a way that is both accessible and affordable. Polarean’s groundbreaking work with Xenon MRI aligns perfectly with our mantra, ‘See Tomorrow Today’. This technology provides an unparalleled ability to visualize lung function, offering critical insights for patients with respiratory conditions such as asthma, COPD, and unexplained dyspnea. Together, we are committed to delivering innovative solutions that have the potential to improve diagnostic accuracy and patient outcomes.”
Christopher von Jako, Ph.D., CEO of Polarean, added : “SimonMed’s dedication to making imaging technologies widely accessible mirrors Polarean’s vision of optimizing lung health and illuminating hidden disease, making SimonMed an ideal collaboration partner. Together, we aim to bring a much-needed imaging tool to clinicians, enabling them to see lung function with unprecedented clarity and precision to help them manage their patients’ disease. We look forward to establishing a strong program in Scottsdale to serve as a model for potential expansion to several additional SimonMed’s sites.”
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com .
About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed o?ers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining a?ordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. For more information, please visit www.SimonMed.com
XENOVIEW IMPORTANT SAFETY INFORMATION
Indication
XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.
Limitations of Use
XENOVIEW has not been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONS
None.
Warnings and Precautions
Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions
Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.
Please see full prescribing information at www.xenoview.net .
Contact Information:
Polarean:
Chuck Osborne
Chief Financial Officer
+1 (919) 206-7900, ext. 117
cosborne@polarean.com
Polarean Investors:
Anna Dunphy / Phillip Marriage
+44 (0)20 7933 8780
polarean@wallbrookpr.com
Polarean Media Contact:
Alexis Opp
+1 (919) 206-7900, ext. 145
aopp@polarean.com
SimonMed PR Contact:
Michelle Kafka
michelle.kafka@kafkamediagroup.com
General inquiries: info@polarean.com
Follow Polarean on LinkedIn here
Attachment
Polarean:Chuck OsborneChief Financial Officer+1 (919) 206-7900, ext. 117cosborne@polarean.comPolarean Investors:Anna Dunphy / Phillip Marriage+44 (0)20 7933 8780polarean@wallbrookpr.comPolarean Media Contact:Alexis Opp+1 (919) 206-7900, ext. 145aopp@polarean.comSimonMed PR Contact:Michelle Kafkamichelle.kafka@kafkamediagroup.comGeneral inquiries: info@polarean.com
FAQ**
How has the strategic collaboration between Polarean Imaging PLC PLLWF and SimonMed Imaging potentially influenced the medical imaging landscape in Durham, NC, compared to its impact in London?
What specific advantages does Polarean Imaging PLC PLLWF’s Xenon MRI platform offer in diagnosing pulmonary diseases, and how do these advantages resonate with local healthcare needs in Durham, NC and London?
Given the growing number of SimonMed facilities adopting the Xenon MRI platform, what implications does this have for Polarean Imaging PLC PLLWF's market expansion plans in Durham, NC, versus its operations in London?
How do the regulatory environments in Durham, NC, and London affect the commercialization strategy of Polarean Imaging PLC PLLWF as it seeks to enhance access to its advanced imaging solutions?
**MWN-AI FAQ is based on asking OpenAI questions about Polarean Imaging PLC (OTC: PLLWF).
NASDAQ: PLLWF
PLLWF Trading
6500.0% G/L:
$0.0066 Last:
5,000 Volume:
$0.0066 Open:
